|Drug class||Radioactive diagnostic agent|
|Main uses||PET imaging of prostate cancer|
|Side effects||Diarrhea, high blood pressure, pain at site of injection|
|Chemical and physical data|
|3D model (JSmol)|
Flotufolastat F-18, sold under the brand name Posluma, is a radioactive diagnostic agent used in positron emission tomography (PET) imaging of prostate cancer. Specifically it is used in prostate-specific membrane antigen (PSMA) positive disease to look for spread or recurrence. It is given by injection into a vein.
Common side effects include diarrhea, high blood pressure, and pain at the site of injection. Other side effects include exposure to radiation. The active ingredient is flotufolastat F-18 gallium.
Flotufolastat F-18 was approved for medical use in the United States in 2023.
- Clinical trial number NCT04186819 for "Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer (LIGHTHOUSE)" at ClinicalTrials.gov
- Clinical trial number NCT04186845 for "Imaging Study to Investigate Safety and Diagnostic Performance of rhPSMA 7.3 (18F) PET Ligand in Suspected Prostate Cancer Recurrence (SPOTLIGHT)" at ClinicalTrials.gov